INS and cancer: In the observational study on new users of insulin glargine (n = 43,306) and human insulin (n = 9147) enrolled in a US health plan, no association with the risk for prostate, breast, colon and any cancer was found for treatment durations of 0–6, 6–12, 12–24 or ≥24 months [38].